The Top 5 Biosimilar Articles for the Week of March 14

Here are the top 5 biosimilar articles for the week of March 14, 2022.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of March 14, 2022.

Number 5: Europe’s Committee for Medicinal Products for Human Use (CHMP) adopted positive opinions for 2 insulin biosimilars, meaning that the agency has recommended the European Commission grant them marketing authorization.

Number 4: Health Canada has approved Byooviz, a biosimilar referencing Lucentis (ranibizumab), for the treatment for several ophthalmic conditions. Byooviz represents the first ranibizumab biosimilar to be approved for the Canadian market.

Number 3: Teva Pharmaceuticals launched lenalidomide capsules, the generic of Revlimid, in the United States. The capsules are available in 5 mg, 10 mg, 15 mg, and 25 mg strengths, according to a statement from the company.

Number 2: AbbVie settled outstanding lawsuits, including its case related to the International Trade Commission (ITC), with Alvotech, giving Alvotech the green light to launch its high-concentration, citrate-free adalimumab biosimilar referencing Humira in July 2023, pending FDA approval.

Number 1: At a session at the Association of Community Cancer Centers’ 2022 Annual Meeting & Cancer Center Business Summit, panelists suggested that the quest for rebates by pharmacy benefit managers (PBMs) prevents uptake on some biosimilars—and could soon bleed over into biosimilar formulary placement.

To read all of these articles and more, visit centerforbiosimilars.com.